Qinpei Wu

Prof. Dr. Qinpei Wu

School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Beijing 102488, China

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2004 in Synthesis
Verified
Journal Article
Closed access
PDF file
Qinpei WuQinpei Wu
Qinpei Wu
CSClaire Simons
Claire Simons
The study and synthesis of C-nucleosides has been extensive owing to their biological activity and potential as drug candidates for antiviral and anticancer therapy. Numerous synthetic strategies have also been investigated in order to optimize yields and stereoselectivity in the glycosylation reaction. Here we review one class of synthetic methods, direct condensation of a pre-formed aglycon unit with an appropriate sugar component.

21 October 2020 in ACS Nano
Verified
Journal Article
Closed access
JZJimei Zhang
Jimei Zhang
BZBaochang Zhao
Baochang Zhao
SCShizhu Chen
Shizhu Chen
YWYongchao Wang
Yongchao Wang
YZYuxuan Zhang
Yuxuan Zhang
HXHaihua Xiao
Haihua Xiao

1 January 2010 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
JYJin-Lan Yu
Jin-Lan Yu
Qinpei WuQinpei Wu
Qinpei Wu
QZQing-Shan Zhang
Qing-Shan Zhang
YLYan-Hong Liu
Yan-Hong Liu
YLYun-Zheng Li
Yun-Zheng Li
ZZZi-Ming Zhou
Zi-Ming Zhou

1 October 2005 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
CSClaire Simons
Claire Simons
Qinpei WuQinpei Wu
Qinpei Wu
Thet Thet HtarThet Thet Htar
Thet Thet Htar
Recent developments in nucleoside/nucleotide therapeutics and antiviral drug targets are described covering progress in the development of nucleoside/nucleotide mimetics for the treatment of influenza virus, human immunodeficiency virus type 1, hepatitis B and C virus, herpes virus infections; including herpes simplex virus, cytomegalovirus and varicella zoster virus infections, and the highly pathogenic poxviruses (variola, vaccinia and mokey pox) and filoviruses (Ebola and Marburg).

18 August 2003 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
CRColin B. Reese
Colin B. Reese
Qinpei WuQinpei Wu
Qinpei Wu
The synthesis of 2-amino-5-(2-deoxy-β-D-ribofuranosyl)pyridine 2a, 2-amino-5-(2-deoxy-α-D-ribofuranosyl)pyridine 23, 2-amino-5-(2-deoxy-β-D-ribofuranosyl)-3-methylpyridine 2b, 2-amino-5-(2-deoxy-α-D-ribofuranosyl)-3-methylpyridine 29 and 5-(2-deoxy-β-D-ribofuranosyl)-2,4-dioxopyrimidine [2′-deoxypseudouridine] 30a is described. These C-nucleosides are prepared either from 2-deoxy-3,5-O-(1,1,3,3-tetraisopropyldisiloxan-1,3-diyl)-D-ribofuranose 15 or from 2-deoxy-3,5-O-(1,1,3,3-tetraisopropyldisiloxan-1,3-diyl)-D-ribono-1,4-lactone 16, which are themselves prepared from 2-deoxy-D-ribose 13. The sugar derivatives are first allowed to react with the appropriate 5-lithio-pyridine or 5-lithio-pyrimidine derivatives, which are prepared from 5-bromo-2-(dibenzylamino)pyridine 12a, 5-bromo-2-[bis(4-methoxybenzyl)amino]pyridine 12b, 5-bromo-2-dibenzylamino-3-methylpyridine 25 and 5-bromo-2,4-bis(4-methoxybenzyloxy)pyrimidine 33. The products from the reactions between the lithio-derivatives and the lactol 15 are cyclized under Mitsunobu conditions; the products from the reactions between the lithio-derivatives and the lactone 16 are first reduced with L-Selectride before cyclization, also under Mitsunobu conditions. In all cases, the β-anomers of the protected C-nucleosides are the predominant products. Finally, the separation of the α- and β-anomers and the removal of all of the protecting groups are described.

3 April 2018 in Advanced Synthesis & Catalysis
Verified
Journal Article
Closed access
PDF file
GWGuang‐Long Wu
Guang‐Long Wu
Qinpei WuQinpei Wu
Qinpei Wu